Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 8.01 (Other Events). Keros partnering with Mass General Hospital to design Phase 2 trial of rinvatercept in ALS patients via HEALEY ALS MyMatch platform.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Keros partnering with Mass General Hospital to design Phase 2 trial of rinvatercept in ALS patients via HEALEY ALS MyMatch platform
- HEALEY MyMatch is a prestigious adaptive trial platform: entry signals clinical validation and accelerates path to data vs. standalone trial design
- Additional Phase 1 healthy volunteer data presented at MDA 2026 Conference, supporting rinvatercept's clinical profile ahead of Phase 2 advancement
- ALS expansion broadens rinvatercept's addressable market beyond existing indications, a potential pipeline catalyst for KROS
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.